Despite the availability of free, effective treatment for HIV, more thanone million people die of AIDS every year in sub-Saharan Africa. Increasing antiretroviral treatment coverage is a necessity, from both a global health and a moral perspective (Collier et al. 2015). The need to increase treatment has implications for both the supply side and the demand side of treatment provision.
RethinkHIV is a consortium of senior researchers from London School of Hygiene & Tropical Medicine, Imperial College London, Harvard School of Public Health, Centre for the Study of African Economies and Blavatnik School of Government at Oxford University.
The consortium will evaluate new evidence related to the costs, benefits, effects, fiscal implications, and developmental impacts of HIV interventions in sub-Saharan Africa, in order to maximise contributions to the fight against HIV there.
The aim of RethinkHIV is to find ways of creating, optimising, and sustaining fiscal space for domestic HIV investment, as well as exploring long-term, sustainable national and international financing mechanisms. RethinkHIV is funded by RUSH Foundation.